To fine-map the AD risk enhancers identified in this study and thus nominate candidate causal variants, we conducted Bayesian fine-mapping in the three loci that were significantly associated with AD risk in the ADGC GWAS (BIN1, MS4A, and ZYX), followed by functional in silico screening of the candidate causal variants for disruption/creation of TF binding motifs. This evidence concerns the gene ZYX and Alzheimer disease.